Development of lung and muscle protein factories to deliver therapeutic monoclonal antibodies

Development of lung and muscle protein factories to deliver therapeutic monoclonal antibodies

Recombinant therapeutic proteins, of which monoclonal antibodies (mAbs) represent the largest market, are used to treat diseases including cancer, blood and immune disorders. The cost and complexity of large-scale production and purification of mAbs translates to high cost of therapy. We hypothesise...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Antepowicz, A, Tan, A, Pringle, A, Hyde, S, Gill, D
Natura:	Conference item
Pubblicazione:	Mary Ann Liebert Inc 2016

Documenti analoghi

Development of lung and muscle factories to deliver therapeutic monoclonal antibodies
di: Antepowicz, A
Pubblicazione: (2018)

431. Lung antibody factory for passive immunisation against influenza
di: Tan, T, et al.
Pubblicazione: (2016)

Lentiviral-mediated expression of monoclonal antibodies in the lung to protect against influenza
di: Du, Y, et al.
Pubblicazione: (2020)

Antibody gene transfer for prophylaxis of respiratory syncytial virus (RSV) infection
di: Antepowicz, A, et al.
Pubblicazione: (2018)

The lung as a factory to produce secreted intrapulmonary and circulatory proteins
di: Paul-Smith, M, et al.
Pubblicazione: (2017)

Development of monoclonal antibody therapeutics for alzheimer's disease
di: Masatoshi Takeda
Pubblicazione: (2022-01-01)

The murine lung as a factory to produce secreted intrapulmonary and circulatory proteins
di: Paul-Smith, M, et al.
Pubblicazione: (2018)

Monoclonal Antibodies as Neurological Therapeutics
di: Panagiotis Gklinos, et al.
Pubblicazione: (2021-01-01)

Therapeutic monoclonal antibody for Sporotrichosis
di: Sandro eAlmeida
Pubblicazione: (2012-11-01)

The development of gene therapy for diseases of the lung.
di: Gill, DR, et al.
Pubblicazione: (2004)

Development of Therapeutic Monoclonal Antibodies for Emerging Arbovirus Infections
di: Leonardo F. Ormundo, et al.
Pubblicazione: (2023-10-01)

Advances and challenges in therapeutic monoclonal antibodies drug development
di: Mariana Lopes dos Santos, et al.
Pubblicazione: (2018-11-01)

Host cell protein profiling of commercial therapeutic protein drugs as a benchmark for monoclonal antibody-based therapeutic protein development
di: Rosalynn Molden, et al.
Pubblicazione: (2021-01-01)

Monoclonal antibodies for the therapeutic induction of tolerance.
di: Waldmann, H, et al.
Pubblicazione: (1993)

Therapeutic potential of monovalent monoclonal antibodies.
di: Cobbold, S, et al.
Pubblicazione: (1984)

The pharmacology and therapeutic applications of monoclonal antibodies
di: María Sofía Castelli, et al.
Pubblicazione: (2019-12-01)

Development and validation of an analytical procedure for the determination of residual protein A in active substances of therapeutic monoclonal antibodies
di: E. V. Nozdrina, et al.
Pubblicazione: (2024-03-01)

Therapeutic Monoclonal Antibodies against Cancer: Present and Future
di: Marisa Delgado, et al.
Pubblicazione: (2023-12-01)

Development of an anti-Pseudomonas aeruginosa therapeutic monoclonal antibody WVDC-5244
di: Alexander M. Horspool, et al.
Pubblicazione: (2023-04-01)

Development and Characterization of Monoclonal Antibodies for the Detection of Fish Protein
di: Yi-Tien Chen, et al.
Pubblicazione: (2021-10-01)

Corrigendum: Therapeutic potential of monovalent monoclonal antibodies
di: Cobbold, S, et al.
Pubblicazione: (1984)

Therapeutic Uses of Monoclonal Antibodies for COVID-19
di: Tarun Kumar Suvvari
Pubblicazione: (2020-01-01)

Intramuscular rAAV2/8 mediated expression of etanercept in mice with collagen-induced arthritis
di: Habib, O, et al.
Pubblicazione: (2019)

Expression profile of optimised SIV vector in the mouse lung at early timepoints post-delivery
di: Pringle, I, et al.
Pubblicazione: (2018)

DEVELOPMENT AND PROPERTIES OF NEUTRALIZING MONOCLONAL ANTIBODIES FOR FUSION PROTEIN OF RESPIRATORY SYNCYTIAL VIRUS
di: A. A. Kushch, et al.
Pubblicazione: (2019-04-01)

Therapeutic potential of monoclonal antibodies to the leucocyte common antigen.
di: Bindon, C, et al.
Pubblicazione: (1985)

Identification and characterisation of candidate monoclonal antibody Ebolavirus therapeutics
di: Donnellan, FR
Pubblicazione: (2021)

Monoclonal antibodies and aptamers: The future therapeutics for Alzheimer's disease
di: Alvaro Barrera-Ocampo
Pubblicazione: (2024-07-01)

Therapeutic monoclonal antibodies with a focus on hereditary angioedema
di: Bruce L. Zuraw, et al.
Pubblicazione: (2023-01-01)

Monoclonal Antibodies Targeting Ion Channels and Their Therapeutic Potential
di: Aurélien Haustrate, et al.
Pubblicazione: (2019-06-01)

The history and potential future of monoclonal antibody therapeutics development and manufacturing in four eras
di: Brian Kelley
Pubblicazione: (2024-12-01)

Developing Monoclonal Antibodies for Immunohistochemistry
di: Jacqueline Cordell
Pubblicazione: (2022-01-01)

Binding of omeprazole to protein targets identified by monoclonal antibodies
di: Naw May Pearl Cartee, et al.
Pubblicazione: (2020-01-01)

Monoclonal antibodies in inflammatory disease of the muscle and peripheral nervous system
di: J.J. Poza Aldea
Pubblicazione: (2012-01-01)

Impact of Urea on Monoclonal Antibodies: Multiple Destabilization and Aggregation Effects for Therapeutic Immunoglobulin G Proteins
di: Ji Young Yang, et al.
Pubblicazione: (2024-01-01)

Monoclonal antibody techniques. 50 years of development
di: Yulia S. Massino, et al.
Pubblicazione: (2024-07-01)

Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins
di: Liming Liu
Pubblicazione: (2017-04-01)

Fc-null anti-PD-1 monoclonal antibodies deliver optimal checkpoint blockade in diverse immune environments
di: C Ian Mockridge, et al.
Pubblicazione: (2022-01-01)

Therapy with monoclonal antibodies. An in vivo model for the assessment of therapeutic potential.
di: Isaacs, J, et al.
Pubblicazione: (1992)

Monoclonal antibodies: a review of therapeutic applications and future prospects
di: Mahmuda, Aliyu, et al.
Pubblicazione: (2017)